Creative Planning raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 9.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,384 shares of the life sciences company’s stock after buying an additional 1,107 shares during the period. Creative Planning’s holdings in Illumina were worth $2,706,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Gateway Investment Advisers LLC increased its stake in shares of Illumina by 3.5% during the fourth quarter. Gateway Investment Advisers LLC now owns 95,711 shares of the life sciences company’s stock worth $20,912,000 after purchasing an additional 3,202 shares during the period. National Pension Service increased its stake in shares of Illumina by 1.2% during the fourth quarter. National Pension Service now owns 137,418 shares of the life sciences company’s stock worth $30,024,000 after purchasing an additional 1,693 shares during the period. Bank of Montreal Can increased its stake in shares of Illumina by 23.5% during the fourth quarter. Bank of Montreal Can now owns 105,906 shares of the life sciences company’s stock worth $23,139,000 after purchasing an additional 20,175 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Illumina by 3.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 13,790 shares of the life sciences company’s stock worth $3,013,000 after purchasing an additional 500 shares during the period. Finally, Private Asset Management Inc. increased its stake in shares of Illumina by 2.2% during the fourth quarter. Private Asset Management Inc. now owns 11,072 shares of the life sciences company’s stock worth $2,419,000 after purchasing an additional 240 shares during the period. Hedge funds and other institutional investors own 91.63% of the company’s stock.

A number of equities analysts have recently weighed in on ILMN shares. Barclays increased their target price on Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $229.00 target price on the stock in a research note on Friday, October 27th. Canaccord Genuity reiterated a “buy” rating and set a $230.00 target price (up previously from $215.00) on shares of Illumina in a research note on Thursday, October 12th. Piper Jaffray Companies reiterated an “overweight” rating and set a $226.00 target price (up previously from $202.00) on shares of Illumina in a research note on Monday, October 9th. Finally, Janney Montgomery Scott upgraded Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $223.88.

In other Illumina news, SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $207.88, for a total value of $334,478.92. Following the sale, the senior vice president now owns 7,217 shares of the company’s stock, valued at approximately $1,500,269.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jay T. Flatley sold 15,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $243.72, for a total value of $3,655,800.00. Following the completion of the sale, the director now directly owns 449,201 shares in the company, valued at approximately $109,479,267.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 134,671 shares of company stock worth $29,417,628. Corporate insiders own 0.89% of the company’s stock.

Illumina, Inc. (ILMN) opened at $245.19 on Tuesday. Illumina, Inc. has a 52 week low of $156.50 and a 52 week high of $248.97. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The company has a market capitalization of $35,800.00, a price-to-earnings ratio of 46.26, a price-to-earnings-growth ratio of 3.27 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same quarter last year, the company earned $0.97 EPS. The company’s revenue was up 17.6% on a year-over-year basis. equities analysts forecast that Illumina, Inc. will post 3.77 earnings per share for the current year.

WARNING: “Illumina, Inc. (ILMN) Shares Bought by Creative Planning” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/illumina-inc-ilmn-shares-bought-by-creative-planning/1819175.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.